Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Assessment of Incidence of Distress and Utilization of Supportive Care Services in Multiple Myeloma Patients, a Retrospective Single Center Experience

Hamid Ehsan, Myra Robinson, Patrick Meadors, Rushil Patel, Shanice Borden, Peter M. Voorhees, Delcan Walsh, Barry Paul, Manisha Bhutani, Cindy Varga, Shebli Atrash

Blood (2023) 142 (Supplement 1): 7416.

https://doi.org/10.1182/blood-2023-178114

Published: 2023

Journal Articles

Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Manisha Bhutani, Myra Robinson, Shebli Atrash, Barry Paul, Mauricio Pineda-Roman, David Foureau, Cindy Varga, Reed Friend, Xhevahire Begic, Sarah Norek, Tiffany Drennan, Michelle B Anderson, James Symanowski, Peter M. Voorhees, Saad Z Usmani

Blood (2023) 142 (Supplement 1): 3380.

https://doi.org/10.1182/blood-2023-174972

Published: 2023

Journal Articles

Histologic and Molecular Correlates in Patients with AL Amyloidosis in Hematologic Remission but with Persistent Renal Disease

Cindy Varga, Felix Eichinger, Abhijit Naik, Viji Nair, Samih Nasr, Agnes Fogo, Denis Toskic, Matthias Kretzler, Raymond Comenzo

Blood (2023) 142 (Supplement 1): 4782.

https://doi.org/10.1182/blood-2023-186632

Published: 2023

Journal Articles

Patterns of Outpatient IVIG Use before and during the COVID Pandemic in Patients with Multiple Myeloma

Jonathan Lambird, John T Mckay, Meng-Yun Lin, Lindsey Abdelfattah, Manisha Bhutani, Barry Paul, Peter M. Voorhees, Cindy Varga, Shebli Atrash, David Duane Hurd

Blood (2023) 142 (Supplement 1): 6634.

https://doi.org/10.1182/blood-2023-180345

Published: 2023

Journal Articles

Serum Proteomic Profiling to Identify Biomarkers of Progression from Monoclonal Gammopathy of Unknown Significance (MGUS) to Multiple Myeloma (MM) Among African Americans and Whites

Cindy Varga, Kip Zimmerman, David Foureau, Sumaiya A Nazli, Peter M. Voorhees, Michael Olivier, Manisha Bhutani

Blood (2023) 142 (Supplement 1): 6597.

https://doi.org/10.1182/blood-2023-179385

Published: 2023

Journal Articles

The Clusterin/Von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL λ-Type Than from λ-Isotype Monoclonal Gammopathy Patients

Stephanie Scalia, Denis Toskic, Ping Zhou, Mahesh M Mansukhani, Lisa Lee, Sandy W. Wong, Sascha A. Tuchman, James E. Hoffman, Teresa Fogaren, Cindy Varga, Suzanne Lentzsch, Raymond Comenzo

Blood (2022) 140 (Supplement 1): 10120–10121.

https://doi.org/10.1182/blood-2022-162352

Published: 2022

Journal Articles

Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)

Manisha Bhutani, Myra Robinson, Barry Paul, Shebli Atrash, Cindy Varga, Xhevahire Begic, David M Foureau, Mauricio Pineda-Roman, Brinda Koya, Sarah Norek, Sara A Sutton, Michelle B Anderson, Donna Acampora, James T Symanowski, Peter M. Voorhees, Saad Usmani

Blood (2022) 140 (Supplement 1): 4440–4441.

https://doi.org/10.1182/blood-2022-160204

Published: 2022

Journal Articles

Gene Expression Sets and Renal Profiling from the Rain (Renal AL Amyloid Involvement and NEOD00) Trial

Cindy Varga, Raymond Comenzo, Agnes Fogo, Samih Nasr, Matthias Kretzler, Viji Nair, Felix Eichinge, Abhijit Naik

Blood (2022) 140 (Supplement 1): 12450–12451.

https://doi.org/10.1182/blood-2022-162914

Published: 2022

Journal Articles

Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)

Blood (2022) 140 (Supplement 1): 4393–4395.

https://doi.org/10.1182/blood-2022-160071

Published: 2022

Journal Articles

Next Generation Sequencing Identifies Light-Chain Amyloid (AL)-Related Igvl Genes in Patients with λ Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

Ping Zhou, Mahesh M Mansukhani, Denis Toskic, Stephanie Scalia, Lisa Lee, Sandy W. Wong, Sascha A. Tuchman, James E. Hoffman, Teresa Fogaren, Cindy Varga, Suzanne Lentzsch, Raymond Comenzo

Blood (2022) 140 (Supplement 1): 10048–10049.

https://doi.org/10.1182/blood-2022-157790

Published: 2022

Journal Articles

Pattern of Use and Outcomes of Daratumumab Therapy in Patients with Multiple Myeloma in a Real-World Setting: A Single Institution Experience

Danai Dima, MD, Xiao Hu, MD MPH, Joshua Dower, MD, Raymond L. Comenzo, MD, Cindy Varga, MDBSc

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-139741

Published: 2020

Journal Articles

Pattern of Use and Efficacy of Daratumumab-Based Therapy in Patients with AL Amyloidosis: A Single Institution Experience

Danai Dima, MD, Xiao Hu, MD MPH, Joshua Dower, MD, Raymond L. Comenzo, MD, Cindy Varga, MDBSc

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-139643

Published: 2020

Journal Articles

Outcomes of Patients with Multiple Myeloma Harboring Gain/Amplification 1q in the Era of Modern Therapy

Xiao Hu, MD MPH, Cherng-Horng Wu, MD, Janet Cowan, PhD, Raymond L. Comenzo, MD, Cindy Varga, MDBSc

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-139780

Published: 2020

Journal Articles

Therapeutic Activity of Combining BCL-2 and HMG-CoA Reductase Inhibition in Systemic Light-Chain Amyloidosis

Ping Zhou, MDPhD, Hashim Mann, MD, Xun Ma, DMD, MSc, PhD, Teresa Fogaren, NP, Yifei Zhang, MD, Denis Toskic, BS, Chakra P Chaulagain, MD, Cindy Varga, MDBSc, Raymond L. Comenzo, MD, Amandeep Godara, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-142656

Published: 2020

Journal Articles

B-Cell Maturation Antigen (BCMA) in Systemic Light-Chain Amyloidosis (AL): Association with Disease Activity and Its Modulation with Gamma-Secretase Inhibition

Amandeep Godara, MD, Ping Zhou, MD PhD, Benjamin Rosenthal, BS, Adin Kugelmass, BSc, Denis Toskic, BS, Teresa Fogaren, NP, Cindy Varga, MD BSc, Raymond L Comenzo, MD

Blood (2019) 134 (Supplement_1): 4409.

https://doi.org/10.1182/blood-2019-126988

Published: 2019

Journal Articles

The Use of Next Generation Gene Sequencing to Measure Minimal Residual Disease in Patients with AL Amyloidosis and Low Plasma Cell Burden: A Feasibility Study

Shayna Sarosiek, Vaishali Sanchorawala, MD, Mariateresa Fulcinti, Allison P. Jacob, Nikhil C. Munshi, MD, Cindy Varga, MD BSc

Blood (2019) 134 (Supplement_1): 4353.

https://doi.org/10.1182/blood-2019-131863

Published: 2019

Journal Articles

Monoclonal Gammopathies and Their Significance: A Retrospective Analysis of Monoclonal Gammopathy and Renal Disease

Anupama Kumar, MD, David Drew, MD, Leslie Inker, MD, Raymond L Comenzo, MD, Cindy Varga, MD BSc

Blood (2019) 134 (Supplement_1): 5498.

https://doi.org/10.1182/blood-2019-127618

Published: 2019

Journal Articles

Histologic and Molecular Correlates in Patients with AL Amyloidosis in Remission but with Persistent Renal Disease

Cindy Varga, MD BSc, Viji Nair, PhD, Agnes Fogo, MD, Samih Nasr, MD, Bradley Godfrey, PhD, Felix Eichinge, PhD, Denis Toskic, BS, Matthias Kretzler, MD, Raymond L Comenzo, MD

Blood (2019) 134 (Supplement_1): 5500.

https://doi.org/10.1182/blood-2019-123228

Published: 2019

Journal Articles

Another Obesity Paradox: In Cardiac AL Amyloid a Higher BMI Is Associated with a Lower Rate of Cardiac Response

So Yeon Kim, MD, Amanda Vest, MD, Raymond L Comenzo, MD, Cindy Varga, MD BSc

Blood (2019) 134 (Supplement_1): 5502.

https://doi.org/10.1182/blood-2019-123890

Published: 2019

Journal Articles

In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels < 10mg/L Are Associated with Optimal Long-Term Survival

Amandeep Godara, MD, Denis Toskic, BS, Benjamin Rosenthal, BS, Cindy Varga, MD BSc, Adin Kugelmass, BSc, Ping Zhou, MD PhD, Teresa Fogaren, NP, Raymond L Comenzo, MD

Blood (2019) 134 (Supplement_1): 4369.

https://doi.org/10.1182/blood-2019-127004

Published: 2019

NARROW

Assessment of Incidence of Distress and Utilization of Supportive Care Services in Multiple Myeloma Patients, a Retrospective Single Center Experience

Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Histologic and Molecular Correlates in Patients with AL Amyloidosis in Hematologic Remission but with Persistent Renal Disease

Patterns of Outpatient IVIG Use before and during the COVID Pandemic in Patients with Multiple Myeloma

Serum Proteomic Profiling to Identify Biomarkers of Progression from Monoclonal Gammopathy of Unknown Significance (MGUS) to Multiple Myeloma (MM) Among African Americans and Whites

The Clusterin/Von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL λ-Type Than from λ-Isotype Monoclonal Gammopathy Patients

Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)

Gene Expression Sets and Renal Profiling from the Rain (Renal AL Amyloid Involvement and NEOD00) Trial

Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)

Next Generation Sequencing Identifies Light-Chain Amyloid (AL)-Related Igvl Genes in Patients with λ Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

Pattern of Use and Outcomes of Daratumumab Therapy in Patients with Multiple Myeloma in a Real-World Setting: A Single Institution Experience

Pattern of Use and Efficacy of Daratumumab-Based Therapy in Patients with AL Amyloidosis: A Single Institution Experience

Outcomes of Patients with Multiple Myeloma Harboring Gain/Amplification 1q in the Era of Modern Therapy

Therapeutic Activity of Combining BCL-2 and HMG-CoA Reductase Inhibition in Systemic Light-Chain Amyloidosis

B-Cell Maturation Antigen (BCMA) in Systemic Light-Chain Amyloidosis (AL): Association with Disease Activity and Its Modulation with Gamma-Secretase Inhibition

The Use of Next Generation Gene Sequencing to Measure Minimal Residual Disease in Patients with AL Amyloidosis and Low Plasma Cell Burden: A Feasibility Study

Monoclonal Gammopathies and Their Significance: A Retrospective Analysis of Monoclonal Gammopathy and Renal Disease

Histologic and Molecular Correlates in Patients with AL Amyloidosis in Remission but with Persistent Renal Disease

Another Obesity Paradox: In Cardiac AL Amyloid a Higher BMI Is Associated with a Lower Rate of Cardiac Response

In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels < 10mg/L Are Associated with Optimal Long-Term Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only